{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:05:43Z","timestamp":1770984343233,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.drugalcdep.2004.12.008","type":"journal-article","created":{"date-parts":[[2005,2,11]],"date-time":"2005-02-11T14:16:45Z","timestamp":1108131405000},"page":"113-116","source":"Crossref","is-referenced-by-count":83,"title":["The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?"],"prefix":"10.1016","volume":"79","author":[{"given":"Lynn E.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Chawarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick G.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard S.","family":"Schottenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Fiellin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2004.12.008_bib1","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1080\/10550490490440780","article-title":"French field experience with buprenorphine","volume":"13","author":"Auriacombe","year":"2004","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2004.12.008_bib2","unstructured":"Drug Addiction Treatment Act, 2000. Pub. L. No. 106\u2013310 (October 17, 2000)."},{"key":"10.1016\/j.drugalcdep.2004.12.008_bib3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMcp013579","article-title":"Clinical practice office-based treatment of opioid dependent patients","volume":"347","author":"Fiellin","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2004.12.008_bib4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-137-8-200210150-00014","article-title":"New federal initiatives to enhance the medical treatment of opioid dependence","volume":"137","author":"Fiellin","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2004.12.008_bib5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"2 Suppl. 1","key":"10.1016\/j.drugalcdep.2004.12.008_bib6","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","article-title":"From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States","volume":"70","author":"Jaffe","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2004.12.008_bib7","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1080\/10550490490440799","article-title":"Implementing buprenorphine treatment in community settings in Austrailia: experiences from the buprenorphine implementation trial","volume":"13","author":"Lintzeris","year":"2004","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2004.12.008_bib8","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA), 2003. Treatment Episode Data Set (TEDS): 1992\u20132001, vol. 2003. Last accessed March 23, 2004, http:\/\/wwwdasis.samhsa.gov\/teds01\/TEDS2K1Index.htm."},{"key":"10.1016\/j.drugalcdep.2004.12.008_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10550490490265271","article-title":"Hepatitis C and HIV infections: implications for clinical care in injection drug users","volume":"13","author":"Sullivan","year":"2004","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2004.12.008_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0740-5472(01)00189-1","article-title":"Practice-based buprenorphine maintenance treatment (BMT): how do French healthcare providers manage the opiate-addicted patients?","volume":"21","author":"Vignau","year":"2001","journal-title":"J. Subst. Abuse Treat."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871605000165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871605000165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T18:56:49Z","timestamp":1548701809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871605000165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0376871605000165"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2004.12.008","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}